1. Home
  2. CYTK vs MMS Comparison

CYTK vs MMS Comparison

Compare CYTK & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • MMS
  • Stock Information
  • Founded
  • CYTK 1997
  • MMS 1975
  • Country
  • CYTK United States
  • MMS United States
  • Employees
  • CYTK N/A
  • MMS N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • MMS Business Services
  • Sector
  • CYTK Health Care
  • MMS Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • MMS Nasdaq
  • Market Cap
  • CYTK 4.6B
  • MMS 4.8B
  • IPO Year
  • CYTK 2004
  • MMS 1997
  • Fundamental
  • Price
  • CYTK $60.16
  • MMS $84.08
  • Analyst Decision
  • CYTK Strong Buy
  • MMS Buy
  • Analyst Count
  • CYTK 15
  • MMS 1
  • Target Price
  • CYTK $76.73
  • MMS $90.00
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • MMS 463.3K
  • Earning Date
  • CYTK 11-05-2025
  • MMS 11-20-2025
  • Dividend Yield
  • CYTK N/A
  • MMS 1.43%
  • EPS Growth
  • CYTK N/A
  • MMS 12.65
  • EPS
  • CYTK N/A
  • MMS 5.37
  • Revenue
  • CYTK $87,211,000.00
  • MMS $5,428,731,000.00
  • Revenue This Year
  • CYTK $363.61
  • MMS $3.80
  • Revenue Next Year
  • CYTK $64.33
  • MMS $2.20
  • P/E Ratio
  • CYTK N/A
  • MMS $15.66
  • Revenue Growth
  • CYTK 2609.26
  • MMS 3.40
  • 52 Week Low
  • CYTK $29.31
  • MMS $63.77
  • 52 Week High
  • CYTK $64.13
  • MMS $92.63
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 55.21
  • MMS 41.60
  • Support Level
  • CYTK $58.05
  • MMS $80.59
  • Resistance Level
  • CYTK $61.29
  • MMS $84.81
  • Average True Range (ATR)
  • CYTK 2.60
  • MMS 1.93
  • MACD
  • CYTK -0.48
  • MMS -0.28
  • Stochastic Oscillator
  • CYTK 57.88
  • MMS 38.87

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Share on Social Networks: